Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension
Abstract Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Pulmonary Circulation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pul2.12426 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850261208334073856 |
|---|---|
| author | Tejaswini P. Reddy Roberto Barrios Eric Bernicker Wei Qian Jenny Chang Zeenat Safdar |
| author_facet | Tejaswini P. Reddy Roberto Barrios Eric Bernicker Wei Qian Jenny Chang Zeenat Safdar |
| author_sort | Tejaswini P. Reddy |
| collection | DOAJ |
| description | Abstract Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may be potential therapeutic targets for PAH. We present a case of a patient with connective tissue disease (CTD)‐associated PAH treated on triple therapy who developed metastatic lung adenocarcinoma. While on PAH triple‐therapy, she received a combination of carboplatin, pemetrexed, and pembrolizumab. She eventually had a complete pathologic response, no evidence of cancer recurrence, and significant improvement of PAH/overall clinical status. After discontinuation of neoplastic therapy, her clinical status worsened, she eventually passed away, and lung biopsy findings revealed evidence of severe pulmonary smooth muscle cell hypertrophy and pulmonary veno‐occlusive disease. This report suggests that combined chemotherapy and immunotherapy may influence the efficacy of PAH therapies and improve clinical status. |
| format | Article |
| id | doaj-art-48df7642be5540f6b68bec7752a20a82 |
| institution | OA Journals |
| issn | 2045-8940 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj-art-48df7642be5540f6b68bec7752a20a822025-08-20T01:55:28ZengWileyPulmonary Circulation2045-89402024-07-01143n/an/a10.1002/pul2.12426Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertensionTejaswini P. Reddy0Roberto Barrios1Eric Bernicker2Wei Qian3Jenny Chang4Zeenat Safdar5Texas A&M University School of Medicine Bryan Texas USADepartment of Pathology and Genomic Medicine Houston Methodist Hospital Houston Texas USAMedical Oncology Centura Health Denver Colorado USAHouston Methodist Research Institute Houston Texas USAHouston Methodist Research Institute Houston Texas USAHouston Methodist Research Institute Houston Texas USAAbstract Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may be potential therapeutic targets for PAH. We present a case of a patient with connective tissue disease (CTD)‐associated PAH treated on triple therapy who developed metastatic lung adenocarcinoma. While on PAH triple‐therapy, she received a combination of carboplatin, pemetrexed, and pembrolizumab. She eventually had a complete pathologic response, no evidence of cancer recurrence, and significant improvement of PAH/overall clinical status. After discontinuation of neoplastic therapy, her clinical status worsened, she eventually passed away, and lung biopsy findings revealed evidence of severe pulmonary smooth muscle cell hypertrophy and pulmonary veno‐occlusive disease. This report suggests that combined chemotherapy and immunotherapy may influence the efficacy of PAH therapies and improve clinical status.https://doi.org/10.1002/pul2.12426carboplatinconnective tissue diseasepembrolizumabpemetrexedpulmonary arterial hypertension |
| spellingShingle | Tejaswini P. Reddy Roberto Barrios Eric Bernicker Wei Qian Jenny Chang Zeenat Safdar Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension Pulmonary Circulation carboplatin connective tissue disease pembrolizumab pemetrexed pulmonary arterial hypertension |
| title | Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| title_full | Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| title_fullStr | Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| title_full_unstemmed | Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| title_short | Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| title_sort | use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension |
| topic | carboplatin connective tissue disease pembrolizumab pemetrexed pulmonary arterial hypertension |
| url | https://doi.org/10.1002/pul2.12426 |
| work_keys_str_mv | AT tejaswinipreddy useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension AT robertobarrios useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension AT ericbernicker useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension AT weiqian useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension AT jennychang useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension AT zeenatsafdar useofcombinedchemotherapyandimmunotherapyimprovespulmonaryarterialhypertension |